WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update.
Read more at globenewswire.comARCA biopharma Announces First Quarter 2022 Financial Results
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here